key
step
ebola
viru
ebov
replic
cycl
involv
conform
chang
viral
glycoprotein
facilit
hostvir
membran
fusion
subsequ
releas
viral
genom
ebola
play
critic
role
viru
entri
similar
mechan
structur
hiv
protein
inhibitor
success
develop
work
put
bind
pocket
ctermin
heptad
repeat
ntermin
heptad
repeat
trimer
target
identif
small
molecul
arrest
ebovhost
membran
fusion
two
comput
structurebas
virtual
screen
compound
perform
dock
program
fivehelix
bundl
result
commerci
avail
compound
purchas
experiment
test
base
assess
inhibitori
activ
cytotox
target
specif
four
promis
candid
emerg
inhibitori
concentr
valu
rang
molecular
dynam
simul
two
potent
candid
dockpredict
bind
pose
indic
major
favor
interact
involv
seven
highli
conserv
residu
use
guid
inhibitor
develop
refin
target
ebov
import
recent
ebola
viru
diseas
outbreak
result
approxim
individu
becom
infect
led
causal
worldwid
particularli
high
pathogen
viru
make
paramount
identif
develop
promis
lead
compound
serv
inhibitor
ebola
infect
limit
viral
load
virushost
membran
fusion
event
target
inhibit
class
fusion
glycoprotein
ebolaviru
current
work
sever
promis
smallmolecul
inhibitor
target
glycoprotein
identifi
systemat
applic
structurebas
comput
experiment
drug
design
procedur
ular
model
tool
experiment
character
specif
largescal
virtual
screen
million
small
molecul
perform
use
program
hypothes
small
molecul
interact
nhr
pocket
interfer
assembl
requir
ebovhost
membran
fusion
fig
interf
format
strategi
previous
employ
success
hiv
target
analog
pocket
viral
protein
comput
screen
result
priorit
purchas
compound
experiment
character
led
hit
inhibit
viral
entri
ebovgppseudotyp
viru
ebov
transcriptionand
replicationcompet
viruslik
particl
trvlp
system
compound
evalu
assess
potenti
activ
artifact
use
detergentcontain
experi
ii
specif
ebov
use
vesicular
stomat
viru
glycoprotein
vsvg
pseudotyp
viru
particl
counterscreen
iii
step
within
ebov
replic
cycl
exert
major
inhibitori
activ
use
timeofaddit
toa
analysi
result
suggest
compound
act
specif
inhibit
ebov
entri
attach
prior
virushost
membran
fusion
molecular
dynam
md
simul
conjunct
genom
analysi
identifi
highli
conserv
residu
across
differ
ebola
viru
strain
contribut
major
favor
interact
compound
virtual
screen
outcom
goal
studi
identifi
molecul
inhibit
ebov
infect
interf
interact
requir
format
sixhelix
bundl
sinc
conform
chang
requir
produc
postfus
structur
depend
chr
bind
nhr
region
fig
virtual
screen
approxim
million
compound
conduct
fivehelix
bundl
model
construct
remov
one
chr
highresolut
postfus
structur
pdb
entri
see
materi
method
compound
priorit
led
candid
purchas
experiment
test
fig
employ
five
distinct
score
function
dce
sum
dock
cartesian
van
der
waal
electrostat
energi
fp
vdw
footprint
comparison
van
der
waal
energi
refer
peptid
select
ligand
fp
es
footprint
electrostat
energi
fp
sum
footprint
van
der
waal
electrostat
energi
ts
total
score
combin
dce
sum
fp
sum
larg
number
molecul
priorit
base
structur
spatial
similar
refer
ligand
compos
segment
chr
made
favor
interact
model
fivehelix
bundl
rule
compound
chosen
experiment
test
show
good
overlap
refer
fig
howev
select
base
favor
footprint
similar
fp
somewhat
better
overlap
select
base
dce
ts
fig
consist
visual
inspect
fig
molecul
five
group
share
similar
size
flexibl
mean
molecular
weight
mw
distribut
gmol
number
rotat
bond
tabl
compound
purchas
base
similar
electrostat
es
interact
profil
fp
es
overal
smallest
mw
gmol
fewer
number
rotat
bond
select
ts
list
largest
gmol
tabl
expect
compound
select
use
specif
score
function
tabl
score
function
column
gener
show
best
averag
score
regard
specif
chemic
physic
properti
tabl
properti
column
exampl
compound
priorit
use
dce
sum
function
yield
favor
lower
averag
dce
sum
energi
kcal
mol
obtain
use
function
kcalmol
likewis
molecul
select
use
fp
sum
result
favor
averag
fp
sum
score
group
compound
priorit
use
fp
es
fp
vdw
footprint
compon
score
lowest
second
lowest
respect
among
respect
fp
es
fp
vdw
group
dce
sum
select
group
favor
score
attribut
strong
es
interact
result
averag
dce
es
score
kcalmol
greater
ensembl
averag
kcalmol
overal
strength
dce
sum
score
conjunct
second
smallest
group
term
mw
number
rotat
bond
suggest
dce
sum
list
compound
highli
polar
contrast
ts
list
interact
domin
strong
vdw
interact
due
larger
size
mw
gmol
tabl
consist
fact
fp
sum
part
ts
score
function
fp
score
compon
better
observ
use
dce
sum
howev
overlap
rel
moder
fp
sum
fp
vdw
fp
es
therefor
futur
work
could
explor
increas
contribut
fp
compon
ts
summari
molecular
properti
analysi
confirm
purchas
candid
similar
size
flexibl
divers
term
interact
energi
overlap
refer
peptid
nine
molecul
initi
silico
screen
inhibit
ebovpseudotyp
viru
entri
vitro
compound
identifi
aforement
silico
screen
test
abil
inhibit
ebov
entri
cytotox
ebov
pseudotyp
viru
entri
cell
quantifi
luciferas
signal
normal
cytotox
dimethyl
sulfoxid
dmso
control
yield
infect
signal
per
cell
fraction
maximum
see
materi
method
encouragingli
nine
compound
result
normal
luciferas
signal
fig
blue
addit
observ
luciferas
signal
nine
compound
approxim
standard
deviat
averag
infect
signal
purchas
molecul
although
two
compound
activ
also
cytotox
fig
lower
blue
nine
hit
activ
retain
use
start
point
identif
structur
relat
analog
secondari
comput
screen
see
discuss
secondari
similar
screen
identifi
addit
compound
enhanc
activ
second
similaritybas
comput
screen
conduct
explor
chemic
search
space
around
nine
initi
hit
hit
turn
use
rescor
rerank
top
dock
molecul
initi
screen
identifi
compound
similar
function
threedimension
shape
use
dock
hungarian
similar
hm
score
function
topscor
molecul
nine
uniqu
list
interrog
use
five
addit
function
method
assess
energi
score
dce
similar
initi
hit
footprint
fp
pharmacophor
fm
volum
overlap
vo
tanimoto
figur
compar
dock
geometri
four
initi
hit
gray
overlaid
two
repres
compound
orang
secondari
screen
exampl
except
compound
gener
show
strong
overlap
made
residuebas
interact
pattern
similar
respect
refer
fig
correspond
high
averag
vo
score
low
averag
fp
score
despit
overal
similar
ligand
scaffold
within
group
use
differ
dock
function
gener
result
select
chemic
divers
molecul
atom
level
case
howev
ligand
toprank
candid
across
differ
group
exampl
rank
order
pharmacophor
volum
overlap
yield
topscor
result
fm
vo
suggest
high
structur
function
similar
initi
hit
fig
fm
vo
overal
secondari
virtual
screen
result
select
addit
candid
subsequ
evalu
inhibit
cytotox
ebovpseudotyp
viru
luciferas
signal
standard
deviat
popul
mean
luciferas
signal
use
identifi
addit
hit
moder
low
cytotox
fig
green
prefix
doserespons
character
candid
hivebovgppseudotyp
viru
explor
promis
candid
identifi
two
silico
screen
initi
plu
secondari
term
reduc
infect
effect
cell
viabil
dosedepend
activ
measur
test
fig
compound
exhibit
gener
wellbehav
entri
inhibit
compar
known
control
inhibitor
seemingli
independ
cytotox
especi
observ
inhibitori
concentr
ic
valu
shown
fig
structur
compound
code
name
shown
fig
encouragingli
molecul
exhibit
ic
valu
compar
result
observ
control
inhibitor
ic
condit
fig
tabl
specif
ic
valu
less
ic
valu
less
fig
tabl
accur
cytotox
concentr
result
cell
death
cc
could
obtain
compound
comput
cc
valu
larg
standard
deviat
although
examin
cytotox
curv
suggest
minim
impact
cell
viabil
two
potent
molecul
assay
display
cc
valu
approxim
tabl
hit
observ
cc
valu
greater
select
index
si
cc
ic
valu
also
calcul
higher
si
ratio
potent
safer
compound
project
vivo
examin
data
show
rang
si
valu
pseudotyp
viru
tabl
compound
comput
si
two
hit
greatest
si
si
valu
around
tabl
test
effect
inhibitor
ebov
system
util
viru
particl
size
shape
similar
nativ
ebov
compound
assess
inhibitori
effect
ebov
trvlp
system
variou
concentr
fig
notabl
yield
ic
tabl
particular
interest
compar
linear
regress
analysi
ic
observ
candid
ebovpseudotyp
viru
trvlp
yield
r
valu
n
increas
n
remov
outlier
tabl
expect
base
good
correspond
two
doserespons
assay
remain
potent
compound
ic
fig
tabl
furthermor
exhibit
ic
approxim
pseudotyp
experi
compound
found
ic
greater
rang
si
valu
trvlp
experi
five
candid
yield
select
indic
greater
tabl
aforement
five
inhibitor
two
compound
largest
si
valu
tabl
summari
result
indic
good
reproduc
pseudotyp
viru
trvlp
assay
affirm
observ
activ
test
hit
specif
candid
ebovgp
hit
also
examin
use
comput
experiment
method
ascertain
observ
activ
involv
nonspecif
effect
result
colloid
aggreg
panassay
interfer
compound
pain
liabil
promiscu
initi
step
assess
whether
activ
result
colloid
compound
screen
structur
similar
known
aggreg
use
aggreg
advisor
http
advisorbkslaborg
eight
candid
exhibit
known
similar
compound
current
databas
three
remain
compound
found
structur
similar
known
aggreg
describ
irwin
shoichet
addit
deterg
lead
decreas
activ
compound
inhibit
exclus
due
colloid
aggreg
thu
activ
also
test
presenc
tween
tabl
compound
defin
sensit
deterg
ic
valu
without
deterg
similar
ic
rang
without
deterg
overlap
activ
increas
base
criteria
none
hit
appear
sensit
although
classifi
ambigu
due
absenc
comput
error
associ
ic
valu
compound
also
subject
evalu
pain
alert
use
distinct
comput
filter
cbligand
swissadm
compound
pain
warn
occur
three
program
due
possibl
mannich
reaction
despit
warn
opt
retain
compound
earli
stage
given
fact
multipl
fdaapprov
drug
elicit
pain
alert
final
pubchem
search
assess
compound
fig
doserespons
infect
ebov
trvlp
treatment
hit
promis
candid
identifi
assay
use
pseudotyp
viru
retest
ebov
trvlp
molecul
initi
secondari
screen
label
prefix
respect
doserespons
curv
black
cytotox
result
red
gener
replic
experi
n
ic
display
graph
number
biolog
replic
perform
calcul
viral
entri
result
previous
report
activ
multipl
target
ie
whether
promiscu
inhibitor
result
avail
test
independ
studi
prior
work
report
activ
studi
differ
target
inconclus
inhibitor
experi
nonspecif
inhibitor
steroidogen
acut
regulatori
protein
bioassay
aid
http
due
appar
promiscu
consid
counterscreen
use
vsv
perform
experiment
determin
specif
priorit
set
compound
procedur
similar
ebovpseudotyp
viru
screen
fig
cell
treat
dmso
ebov
inhibitor
nonspecif
endosom
acidif
inhibitor
bafilomycin
candid
fig
compound
test
due
low
cc
tabl
candid
test
notabl
compound
show
less
inhibitori
activ
vsvg
screen
fig
initi
ebovgp
screen
luciferas
signal
fig
four
compound
least
averag
inhibitori
activ
vsvg
therefor
like
higher
specif
ebov
fig
hit
show
minim
effect
cell
viabil
base
aforement
analysi
although
compound
shown
fig
would
also
promis
explor
stage
select
character
candid
compound
exhibit
maxim
inhibit
postattach
membran
fusion
explor
stage
ebov
entri
cascad
candid
act
timeofaddit
toa
experi
perform
fig
four
compound
show
specif
suggest
averag
activ
result
depict
fig
toa
assay
cell
treat
four
candid
cathepsin
inhibitor
variou
time
point
postinfect
compound
test
concentr
requir
reach
maximum
inhibit
without
signific
effect
cell
viabil
describ
doserespons
curv
pseudotyp
viru
fig
tabl
importantli
four
candid
molecul
exhibit
activ
trend
similar
known
control
maximum
inhibit
occur
time
point
began
decreas
fig
fact
compound
track
suggest
act
pinocytosi
cleavag
bind
form
prior
fusion
step
expect
molecul
target
disrupt
interact
chr
nhr
necessari
format
exhibit
reproduc
pose
stabil
md
simul
experiment
character
concentrationdepend
analysi
counterscreen
toa
experi
suggest
potent
specif
inhibitor
premembran
fusion
stage
ebov
entri
identifi
virtual
screen
fulli
explor
energet
geometr
compat
inhibitor
propos
pocket
atom
md
simul
dockpredict
pose
execut
previous
describ
six
replica
simul
complex
perform
explicit
solvent
replica
employ
differ
random
seed
ligand
movement
quantifi
use
rmsd
root
mean
squar
deviat
account
translat
rotat
differ
intern
geometri
rel
initi
predict
pose
analysi
trajectori
show
four
compound
simul
maintain
dockpredict
pose
close
across
six
simul
observ
reproduc
averag
rmsd
respect
fig
sinc
averag
rmsd
less
equal
close
typic
benchmark
commonli
use
redock
valid
test
addit
character
two
compound
perform
describ
contrast
adopt
wider
varieti
ligand
pose
md
simul
result
larger
rang
rmsd
fig
visual
inspect
show
adopt
two
overal
geometri
md
simul
one
closer
origin
dock
pose
contribut
bimod
rmsd
histogram
fig
gener
compound
show
much
larger
overal
spread
rmsd
mean
result
larger
chang
intern
geometri
andor
movement
pocket
footprint
interact
analysi
step
toward
understand
hypothes
mechan
action
inhibit
sixhelix
bundl
format
interact
character
determin
residu
greatest
contribut
ligandreceptor
interact
across
hit
footprint
interact
profil
gener
compound
energi
obtain
md
trajectori
fig
overal
footprint
show
strike
similar
refer
especi
term
vdw
profil
fig
suggest
good
molecular
mimicri
chr
region
moreov
maintain
strong
contact
similar
degre
residu
consist
overlap
bind
site
structur
similar
residu
favor
interact
across
two
candid
result
combin
averag
energi
greater
fig
regard
es
energi
refer
profil
contain
two
es
peak
correspond
howev
consensu
residu
combin
averag
energi
kcal
mol
less
kcalmol
fig
notabl
also
consider
interact
kcalmol
fig
inspect
individu
footprint
profil
show
interact
slightli
favor
ebov
fivehelix
bundl
across
multipl
residu
addit
instanc
stronger
predict
interact
vdw
kcalmol
es
kcalmol
plot
vdw
kcalmol
es
kcalmol
although
simul
result
slightli
greater
energi
key
residu
fig
energi
candid
within
one
standard
deviat
mean
therefor
insignificantli
differ
highlight
key
residu
interact
refer
ligand
correspond
residu
notabl
favor
vdw
interact
visual
specif
involv
strong
nonspecif
vdw
interact
substitu
phenyl
substitu
fig
addit
although
hit
interact
compound
exhibit
vdw
interact
throughout
approxim
simul
regard
es
interact
two
inhibitor
establish
maintain
strong
es
contact
across
one
main
substitu
throughout
major
md
simul
instanc
proton
nitrogen
methylpiperidin
substitu
maintain
watermedi
hydrogenbond
interact
backbon
sidechain
direct
hydrogenbond
interact
sidechain
time
fig
hand
retain
watermedi
interact
approxim
simul
direct
hydrogenbond
interact
total
approxim
simul
fig
summari
result
suggest
potenti
establish
retain
strong
vdw
es
interact
predict
bind
site
sequenc
conserv
across
key
residu
assess
whether
inhibitor
potenti
interact
favor
ebolaviru
speci
relat
filovirida
virus
comprehens
sequenc
align
studi
conduct
specif
human
sampl
sequenc
contain
complet
gp
genom
five
known
ebolaviru
speci
zair
bundibugyo
reston
sudan
tai
forest
select
via
viru
pathogen
resourc
vipr
databas
wwwviprbrcorg
nih
addit
viru
sequenc
select
use
blast
base
similar
core
sequenc
pdb
entri
use
conduct
virtual
screen
multiplesequ
align
perform
use
cobalt
align
abovement
sequenc
fullgenom
sequenc
zair
ebolaviru
strain
genbank
access
number
ultim
sequenc
seen
human
nonhuman
primat
retain
fragment
complet
gp
sequenc
use
sequenc
comparison
analysi
fig
consist
previou
studi
high
sequenc
ident
core
region
except
intent
mutat
introduc
facilit
crystal
comparison
genom
complet
sequenc
residu
exhibit
approxim
conserv
fig
bottom
notabl
zair
sequenc
common
pathogen
show
sequenc
similar
seven
key
residu
identifi
mdbase
footprint
analysi
show
greater
conserv
across
sequenc
zair
particular
conserv
overal
high
sequenc
conserv
among
subset
survey
genom
five
ebolaviru
speci
repres
exampl
shown
fig
suggest
potenti
interact
seven
key
residu
analog
bind
site
fig
shade
bar
therebi
inhibit
sequenc
variant
zair
ebolaviru
differ
ebolaviru
speci
howev
experiment
test
would
requir
character
activ
small
molecul
differ
virus
ebov
particl
enter
cell
macropinocytosi
later
traffick
endosom
conform
chang
induc
viral
envelop
protein
lead
membran
fusion
conform
chang
three
chr
region
bind
nhr
trimer
form
sixhelix
bundl
mediat
hostviru
membran
fusion
due
current
lack
fdaapprov
therapeut
avail
treat
evd
key
involv
viru
entri
studi
focus
identif
smallmolecul
lead
inhibit
format
necessari
viru
entri
target
interfac
chr
interact
nhr
import
howev
note
dock
model
approxim
ebov
prehairpin
thu
like
reflect
subtleti
inher
actual
biolog
system
nevertheless
approach
success
use
group
prior
work
led
identif
entri
inhibitor
target
hiv
believ
adapt
method
target
ebola
reason
strategi
work
initi
virtual
screen
follow
second
similar
screen
perform
priorit
molecul
energet
favor
interact
nhr
pocket
led
total
compound
experiment
test
appear
promis
ebovpseudotyp
viru
entri
assay
subsequ
doserespons
analys
narrow
group
inhibitor
low
moder
cytotox
valid
activ
hit
test
ebov
trvlp
similar
shape
size
nativ
viru
trvlp
result
correspond
well
obtain
use
pseudotyp
viru
affirm
hit
promis
ebov
inhibitor
probe
specif
hit
also
test
use
vsvgpseudotyp
viruslik
particl
fig
stage
four
compound
priorit
addit
analysi
given
strong
inhibit
low
cytotox
appar
specif
ebov
timeofaddit
assay
control
curv
show
maxim
level
inhibitori
activ
occur
time
time
point
inhibit
start
decreas
fig
consist
studi
lag
ebov
entri
pathway
compar
influenza
viru
due
traffick
late
endosomelysosom
time
loss
inhibit
experiment
compound
report
mingo
et
al
occur
full
restor
infect
time
point
contrast
full
infect
restor
system
approxim
h
could
due
differ
vlp
cell
type
readout
assay
importantli
four
hit
exhibit
timeofaddit
trend
similar
suggest
act
late
entri
step
bind
although
hit
hypothes
prevent
collaps
metast
intermedi
stabl
possibl
interact
earlier
prefus
conform
could
also
disrupt
interact
partner
protein
lipid
bilay
bilay
compon
disrupt
put
cleavag
step
addit
mechanist
investig
sitedirect
mutagenesi
structur
studi
requir
confirm
hypothesi
hit
inhibit
format
studi
candid
compound
futur
work
analog
addit
target
site
could
uncov
import
detail
fusion
trigger
initi
step
help
valid
inhibitor
prevent
format
steric
energet
compat
hit
explor
via
md
simul
two
hit
reproduc
ligand
pose
lower
rmsd
md
analysi
identifi
seven
key
residu
engag
signific
favor
proteinligand
interact
fig
notabl
residu
highli
conserv
fig
across
differ
ebolaviru
speci
suggest
hit
abil
inhibit
differ
type
evdcaus
virus
compound
identifi
work
efficaci
similar
report
inhibitor
viru
entri
specif
identifi
compound
ic
valu
less
three
hit
ic
valu
less
previous
report
inhibitor
includ
zmapp
combin
three
antibodi
two
appear
prevent
conform
chang
gp
necessari
progress
latestag
entri
estim
ic
valu
zmapp
estim
literatur
valu
report
holtsberg
et
al
gml
exampl
includ
cpeptid
inhibitor
design
concept
success
hiv
peptid
enfuvirtid
prevent
collaps
contrast
hiv
cpeptid
ebov
cpeptid
show
weak
insignific
antivir
activ
due
inabl
access
endosom
compart
howev
inhibit
significantli
improv
research
ad
hiv
tat
protein
transduct
domain
ptd
result
ebotat
hybrid
show
inhibit
peptidebas
inhibitor
includ
prehairpin
intermedi
mimic
report
clinton
et
al
show
midnanomolar
inhibit
pseudotyp
assay
seri
cyclopeptid
ic
valu
rang
term
small
molecul
basu
et
al
report
benzodiazepin
deriv
hypothes
bind
pocket
observ
prefus
conform
inhibit
entri
ic
anoth
studi
identifi
g
proteincoupl
receptor
gpcr
antagonist
benztropin
inhibit
ebov
ic
subsequ
crystallograph
studi
stuart
cowork
show
benztropin
compound
includ
bepridil
paroxetin
sertralin
toremifen
interestingli
ibuprofen
bound
site
thought
destabil
protein
complex
contrast
present
compound
hypothes
stabil
fusion
intermedi
prevent
conform
chang
requir
format
notabl
investig
drug
synergi
report
dyall
et
al
use
fdaapprov
drug
show
major
pair
identifi
synergist
inhibitor
ebola
viru
includ
entri
inhibitor
suggest
worthwhil
determin
synergi
entri
inhibitor
identifi
work
compound
summari
studi
demonstr
util
computeraid
model
conjunct
experiment
test
identifi
four
compound
appear
specif
inhibitor
ebov
entri
target
previous
unexploit
site
ebov
conform
repres
prehairpin
intermedi
util
protein
mimicri
select
smallmolecul
mimic
identifi
inhibitor
hypothes
prevent
format
critic
serv
proof
principl
techniqu
start
point
studi
comput
method
work
sever
comput
method
employ
target
arrang
five
distinct
protocol
bind
site
refer
ligand
design
hotspot
identif
ii
receptor
refer
prepar
iii
dock
receptor
setup
iv
dock
virtual
screen
protocol
compound
priorit
v
md
simul
work
employ
sever
softwar
packag
includ
antechamb
tleap
cpptraj
sander
pmemd
amber
suit
program
univers
california
san
francisco
dm
grid
sphgen
part
dock
suit
program
univers
california
san
francisco
divid
chunk
molecul
compound
flexibl
flx
dock
fivehelix
bundl
parallel
use
mpi
version
univers
california
san
francisco
dock
compound
best
score
pose
retain
energi
minim
use
standard
dock
cartesian
energi
dce
function
finetun
interact
receptor
candid
ligand
permit
footprint
similar
score
similar
vdw
es
interact
profil
refer
screen
molecul
quantifi
use
euclidean
distanc
key
descriptor
comput
program
moe
topscor
molecul
base
dce
score
includ
number
lipinski
violat
number
chiral
center
logp
aid
compound
priorit
moe
macc
cluster
method
concurr
employ
use
bestfirst
approach
group
compound
structur
relat
famili
best
dce
score
compound
per
famili
serv
clusterhead
promot
divers
compound
select
topscor
clusterhead
rank
order
use
five
distinct
score
criteria
sum
van
der
waal
electrostat
dock
cartesian
energi
score
dce
sum
ii
van
der
waal
fp
score
fp
vdw
iii
electrostat
fp
score
fp
es
iv
sum
fp
vdw
fp
es
score
fp
sum
v
combin
dce
sum
fp
sum
score
total
score
ts
follow
visual
inspect
topscor
member
five
list
compound
refer
prefix
initi
screen
purchas
experiment
test
second
set
ligand
refer
prefix
secondari
screen
purchas
base
similar
comparison
hit
identifi
initi
screen
similar
comput
use
follow
score
function
hungarian
similar
footprint
similar
pharmacophor
similar
volum
overlap
screen
addit
ligand
properti
consid
includ
central
locat
pocket
number
chiral
center
less
formal
charg
favor
overal
score
respect
particular
rankord
method
favor
electrostat
score
md
simul
analysi
promis
candid
md
simul
perform
assess
geometr
energet
stabil
accessori
program
antechamb
tleap
use
proton
solvat
assembl
assign
forcefield
paramet
protein
receptor
solvent
ligand
gaff
ligand
partial
charg
obtain
preassign
zinc
databas
fivehelix
bundl
cap
n
terminu
cap
ace
c
terminu
cap
nme
previous
describ
ninestep
protocol
use
equilibr
solvat
ligandprotein
complex
briefli
simul
perform
use
cudaacceler
version
pmemd
short
first
solvent
proteinligand
hydrogen
minim
restraint
weight
kcal
mol
complex
heavi
atom
cycl
second
restraint
lift
entir
complex
minim
cycl
third
ps
system
heat
fourth
short
md
simul
ps
allatom
restraint
weight
kcal
mol
perform
optim
water
box
densiti
lastli
complex
underw
five
equilibr
step
ps
length
lessen
restraint
weight
protein
ligand
heavi
atom
protein
restraint
weight
visual
md
trajectori
conduct
use
vmd
chimera
accessori
program
cpptraj
inhous
protocol
util
extract
vdw
es
energi
distancedepend
dielectr
comput
molecular
footprint
rmsd
root
mean
squar
deviat
hydrogenbond
interact
compound
throughout
md
trajectori
frame
simul
previous
describ
predict
interact
energi
six
replica
md
trajectori
use
calcul
mean
vdw
es
energi
small
molecul
residu
fivehelix
bundl
residu
energi
less
kcalmol
refer
ligand
experiment
verifi
entri
inhibitor
use
select
key
residu
involv
interact
energi
comput
ligand
rmsd
twostep
protocol
execut
first
proteinligand
complex
frame
trajectori
align
use
cpptraj
protein
alpha
carbon
overlap
second
atomiclevel
smallmolecul
translat
rotat
compar
dock
pose
quantifi
interpret
rmsd
bin
base
frequenc
use
cpptraj
plot
use
python
python
softwar
foundat
amber
accessori
program
cpptraj
use
extract
direct
watermedi
hydrogenbond
interact
trajectori
provid
frequenc
locat
frame
experiment
method
experiment
method
character
inhibitori
activ
small
molecul
identifi
silico
screen
describ
three
differ
assay
employ
pseudotyp
util
assess
viral
entri
ii
pseudotyp
util
assess
inhibitor
specif
iii
ebov
trvlp
util
second
confirmatori
assay
viral
entri
cell
line
plasmid
follow
reagent
obtain
aid
reagent
program
divis
aid
niaid
nih
tzmbl
cell
number
j
c
kapp
x
wu
replicationdefect
hiv
vector
number
n
landau
follow
reagent
obtain
bei
resourc
niaid
nih
vector
contain
zair
ebolaviru
glycoprotein
plasmid
pcmvvsvg
gift
e
freed
ncifrederick
ebov
trvlp
transfect
plasmid
pcaggsnp
pcaggsl
gift
h
feldmann
nih
cell
atcc
tzmbl
cell
cultur
dulbecco
modifi
eagl
medium
dmem
corn
supplement
heatinactiv
fetal
bovin
serum
fb
gemini
bioproduct
contain
gml
streptomycin
uml
penicillin
fb
incub
co
atmospher
replicationincompet
pseudotyp
viru
contain
replic
machineri
outer
glycoprotein
either
ebola
vesicular
stomat
viru
prepar
standard
transfect
method
use
polyethylenimin
pei
max
polysci
specif
h
prior
transfect
cell
cell
seed
per
dish
cell
cotransfect
equal
amount
g
core
plasmid
envelop
protein
plasmid
use
g
pei
transfect
reagent
per
plate
twentyfour
h
posttransfect
medium
replac
pseudotyp
viru
harvest
supernat
h
posttransfect
supernat
clarifi
lowspe
centrifug
follow
filtrat
filter
millipor
filter
supernat
centrifug
rpm
h
pellet
resuspend
dulbecco
phosphatebuff
salin
dpb
store
need
infecti
titer
viru
stock
quantifi
stain
tzmbl
cell
ebov
trvlp
prepar
transienttransfectionbas
transcriptionand
replicationcompet
system
model
entir
replic
cycl
biosafeti
level
util
confirm
inhibit
system
physiolog
relev
pseudotyp
viru
due
nativ
size
shape
ebov
particl
prepar
ebov
trvlp
prepar
previous
describ
briefli
cell
seed
ml
plate
confluenc
twentyfour
h
postseed
cell
transfect
follow
plasmid
per
well
ng
ng
pcaggsnp
ng
ng
g
pcaggsl
ng
use
g
pei
transfect
reagent
twentyfour
h
posttransfect
medium
replac
ml
fb
seventytwo
h
posttransfect
supernat
contain
trvlp
pool
clarifi
lowspe
centrifug
store
screen
silicoselect
compound
viral
entri
assay
viral
entri
measur
use
luciferas
report
test
select
compound
control
three
type
viru
particl
ebov
pseudotyp
vsv
pseudotyp
ebov
trvlp
perform
similar
procedur
cell
seed
cellswel
tissu
culturetr
whitebottom
plate
greiner
precoat
gml
linear
pei
sigma
ebov
trvlp
infect
helper
ribonucleoprotein
rnp
compon
must
provid
tran
express
plasmid
transfect
h
postseed
amount
helper
rnp
plasmid
per
well
ng
ng
pcaggsnp
ng
pcaggsl
ng
ng
pei
transfect
reagent
twentyfour
h
postseed
pseudotyp
viru
particl
posttransfect
trvlp
cell
pretreat
select
compound
control
h
medium
remov
cell
infect
viru
particl
also
pretreat
h
h
inoculum
remov
cell
wash
briefli
pb
fresh
medium
ad
plate
incub
h
viral
entri
measur
use
luciferas
report
experi
also
perform
absenc
viru
determin
toxic
select
compound
control
viral
entri
cell
viabil
measur
use
oneglo
tox
luciferas
report
cell
viabil
assay
promega
accord
manufactur
protocol
use
spectra
max
plate
reader
molecular
devic
luciferas
signal
normal
cell
viabil
normal
luciferas
signal
dmsotreat
sampl
compound
infect
signal
per
cell
fraction
maximum
consid
activ
hit
initi
screen
addit
doserespons
assay
inhibitori
concentr
ic
cytotox
concentr
cc
confid
interv
ci
comput
ic
plot
use
prism
graphpad
softwar
la
jolla
california
usa
cc
report
standard
deviat
within
cc
could
calcul
previous
describ
select
control
dissolv
dmso
cathepsin
inhibitor
millipor
cystein
proteas
inhibitor
prevent
cleavag
event
necessari
specif
ebov
fusion
endosom
membran
use
posit
control
inhibit
hivebovgp
ebov
trvlp
assay
neg
control
vsvg
assay
inhibit
vsvg
fusion
action
cell
permeabl
bafilomycin
calbiochem
vacuolar
atpas
inhibitor
prevent
ebov
vsv
entri
alkalin
endosom
use
posit
control
inhibit
assay
cell
infect
either
ebovor
vsvgpseudotyp
viru
multipl
infect
moi
l
ebov
trvlp
indic
tween
sigma
also
ad
assay
test
colloid
aggreg
timeofaddit
assay
cell
seed
cellswel
peipreco
tissu
culturetr
whitebottom
plate
next
day
ebovpseudotyp
viru
ad
cell
moi
plate
centrifug
h
g
allow
viru
attach
cell
synchron
infect
plate
wash
pb
remov
unbound
viru
plate
move
allow
viral
entri
h
small
molecul
control
millipor
ad
plate
variou
time
point
indic
cell
viabil
viral
entri
measur
analyz
h
postinfect
describ
